[go: up one dir, main page]

CY2022013I2 - Καινοτομα πολυμερικα προφαρμακα hgh - Google Patents

Καινοτομα πολυμερικα προφαρμακα hgh

Info

Publication number
CY2022013I2
CY2022013I2 CY2022013C CY2022013C CY2022013I2 CY 2022013 I2 CY2022013 I2 CY 2022013I2 CY 2022013 C CY2022013 C CY 2022013C CY 2022013 C CY2022013 C CY 2022013C CY 2022013 I2 CY2022013 I2 CY 2022013I2
Authority
CY
Cyprus
Prior art keywords
innovative
polymeric hgh
prodrugs
hgh prodrugs
polymeric
Prior art date
Application number
CY2022013C
Other languages
English (en)
Other versions
CY2022013I1 (el
Original Assignee
Ascendis Pharma Growth Disorders Division A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2022013(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ascendis Pharma Growth Disorders Division A/S filed Critical Ascendis Pharma Growth Disorders Division A/S
Publication of CY2022013I2 publication Critical patent/CY2022013I2/el
Publication of CY2022013I1 publication Critical patent/CY2022013I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G17/00—Cultivation of hops, vines, fruit trees, or like trees
    • A01G17/005—Cultivation methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G2/00—Vegetative propagation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G7/00—Botany in general
    • A01G7/06—Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
    • C08G2650/06—Epoxy-capping

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Ecology (AREA)
  • Forests & Forestry (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY2022013C 2014-11-18 2022-05-12 Καινοτομα πολυμερικα προφαρμακα hgh CY2022013I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193603 2014-11-18
EP15797642.4A EP3237014B1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs
PCT/EP2015/076813 WO2016079114A1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs

Publications (2)

Publication Number Publication Date
CY2022013I2 true CY2022013I2 (el) 2023-01-05
CY2022013I1 CY2022013I1 (el) 2023-01-05

Family

ID=51951624

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20211100235T CY1123963T1 (el) 2014-11-18 2021-03-18 Καινοτομα πολυμερικα προφαρμακα hgh
CY2022013C CY2022013I1 (el) 2014-11-18 2022-05-12 Καινοτομα πολυμερικα προφαρμακα hgh

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20211100235T CY1123963T1 (el) 2014-11-18 2021-03-18 Καινοτομα πολυμερικα προφαρμακα hgh

Country Status (27)

Country Link
US (3) US10799563B2 (el)
EP (3) EP4218823A3 (el)
JP (5) JP6783782B2 (el)
KR (3) KR102608645B1 (el)
AU (3) AU2015348633C1 (el)
CA (1) CA2968282A1 (el)
CY (2) CY1123963T1 (el)
DK (2) DK3653227T5 (el)
ES (2) ES2947818T3 (el)
FI (2) FI3237014T3 (el)
FR (1) FR22C1029I2 (el)
HR (1) HRP20210400T4 (el)
HU (2) HUE053855T2 (el)
IL (2) IL251906B2 (el)
LT (2) LT3653227T (el)
LU (1) LUC00256I2 (el)
MX (2) MX394222B (el)
NL (1) NL301172I2 (el)
NO (1) NO2022014I1 (el)
PL (1) PL3653227T6 (el)
PT (1) PT3653227T (el)
RS (1) RS61734B2 (el)
RU (1) RU2718664C2 (el)
SG (2) SG11201703870UA (el)
SI (1) SI3653227T1 (el)
SM (1) SMT202100172T1 (el)
WO (1) WO2016079114A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3050576T3 (pl) 2008-04-29 2021-10-25 Ascendis Pharma Endocrinology Division A/S Pegylowane związki rekombinowanego ludzkiego hormonu wzrostu
BR112012014721B1 (pt) 2009-12-15 2022-06-28 Ascendis Pharma Endocrinology Division A/S Composições de hormônio do crescimento, seus métodos de fabricação, recipiente e kit
IL251906B2 (en) 2014-11-18 2024-04-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric hgh prodrugs
US12016903B2 (en) * 2014-11-21 2024-06-25 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone treatment
IL321464A (en) * 2016-09-29 2025-08-01 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
CA3093083A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
MA52662A (fr) * 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
BR112021011592A2 (pt) 2019-01-04 2021-10-26 Ascendis Pharma Oncology Division A/S Conjugados de agonistas de receptor de reconhecimento de padrão
US20220054476A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
CN113573698A (zh) * 2019-03-04 2021-10-29 阿森迪斯药物内分泌股份有限公司 与每日生长激素相比具有优异功效的长效生长激素剂型
JP2023527919A (ja) 2020-06-03 2023-06-30 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｉｌ－２配列及びその使用
MX2023011059A (es) 2021-04-01 2023-09-29 Ascendis Pharma As Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion.
JP2024544923A (ja) * 2021-11-12 2024-12-05 ベックマン コールター， インコーポレイテッド ポリマー色素がコンジュゲートされた抗体の乾燥のための新規製剤

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
IL78930A0 (en) 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
JPH0531189A (ja) 1991-01-16 1993-02-09 Takeda Chem Ind Ltd ２室型注射器
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
SE9303918L (sv) 1993-11-26 1995-05-22 Hans Lundstroem Anordning vid en box
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6011197A (en) * 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
EP1037649B1 (en) 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001078683A2 (en) 2000-04-19 2001-10-25 Genentech, Inc. Sustained release formulations comprising growth hormone
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
MXPA04004809A (es) 2001-11-20 2004-08-11 Pharmacia Corp Conjugados de hormona de crecimiento humana modificada quimicamente.
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
CA2503594C (en) 2002-11-15 2011-05-10 Doris Brugger Positional isomers of peg ifn alpha 2a
US20040142870A1 (en) 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
WO2005035553A2 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
EP2087910B1 (en) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Polymeric prodrugs
EP1579873A1 (en) * 2004-03-23 2005-09-28 Complex Biosystems GmbH Polymeric prodrugs
EP1625855A1 (en) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
US7959600B2 (en) 2004-12-30 2011-06-14 Byeong S. Chang Container closure delivery system
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
JP2008531482A (ja) 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ Ｃ末端がｐｅｇ化された成長ホルモン
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
MX2007015676A (es) 2005-06-15 2008-02-20 Novo Nordisk Healthcare Ag Conjugacion de la hormona de crecimiento mediada por transglutaminasa.
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
AU2006286486A1 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
KR102109867B1 (ko) 2006-01-24 2020-05-13 안선 바이오파르마, 아이엔씨. 고분자 미소 구체들의 조제를 위한 기술
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2008148839A2 (en) 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
EP2113256A1 (en) * 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
PL3050576T3 (pl) * 2008-04-29 2021-10-25 Ascendis Pharma Endocrinology Division A/S Pegylowane związki rekombinowanego ludzkiego hormonu wzrostu
HUE024541T2 (hu) 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
EP2403537A1 (en) 2009-03-05 2012-01-11 Ascendis Pharma A/S Interferon alpha carrier prodrugs
WO2011003234A1 (zh) 2009-07-08 2011-01-13 深圳市掌网立体时代视讯技术有限公司 光学立体放映装置、系统及方法
LT2459220T (lt) 2009-07-31 2020-12-28 Ascendis Pharma A/S Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
BR112012014721B1 (pt) * 2009-12-15 2022-06-28 Ascendis Pharma Endocrinology Division A/S Composições de hormônio do crescimento, seus métodos de fabricação, recipiente e kit
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
SI2571510T1 (sl) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe
CN104955472A (zh) 2012-10-17 2015-09-30 诺和诺德保健股份有限公司 用于生长激素递送的脂肪酸酰化的氨基酸
IL251906B2 (en) 2014-11-18 2024-04-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric hgh prodrugs
US12016903B2 (en) 2014-11-21 2024-06-25 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone treatment
WO2016109823A1 (en) 2015-01-02 2016-07-07 Amunix Operation Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
CN113573698A (zh) 2019-03-04 2021-10-29 阿森迪斯药物内分泌股份有限公司 与每日生长激素相比具有优异功效的长效生长激素剂型

Also Published As

Publication number Publication date
LTPA2022506I1 (el) 2022-06-10
HRP20210400T1 (hr) 2021-04-16
EP3653227A1 (en) 2020-05-20
US10799563B2 (en) 2020-10-13
HRP20210400T4 (hr) 2022-04-29
LUC00256I2 (el) 2025-03-04
FIC20220017I1 (fi) 2022-06-03
JP6982156B2 (ja) 2021-12-17
NZ769682A (en) 2024-09-27
AU2024201227A1 (en) 2024-03-28
AU2015348633B2 (en) 2020-10-22
EP4218823A2 (en) 2023-08-02
SG11201703870UA (en) 2017-06-29
EP3653227B3 (en) 2022-03-09
WO2016079114A1 (en) 2016-05-26
JP2023052300A (ja) 2023-04-11
US20200390864A1 (en) 2020-12-17
PT3653227T (pt) 2021-02-26
JP7431355B2 (ja) 2024-02-14
IL307773A (en) 2023-12-01
RS61734B1 (sr) 2021-05-31
KR20250059541A (ko) 2025-05-02
NL301172I1 (nl) 2022-04-29
PL3653227T6 (pl) 2022-04-19
EP3237014B1 (en) 2023-03-29
JP7785109B2 (ja) 2025-12-12
DK3653227T6 (da) 2022-04-11
ES2864415T9 (es) 2023-05-23
HUS2200019I1 (hu) 2022-06-28
FI3237014T3 (fi) 2023-06-09
IL251906B2 (en) 2024-04-01
SMT202100172T1 (it) 2021-05-07
LTC3653227I2 (el) 2024-11-25
AU2020270494A1 (en) 2020-12-17
AU2015348633A1 (en) 2017-05-18
KR102608645B1 (ko) 2023-12-01
RU2017121203A (ru) 2018-12-19
US20250032587A1 (en) 2025-01-30
PL3653227T3 (pl) 2021-07-05
NZ731779A (en) 2021-11-26
JP6783782B2 (ja) 2020-11-11
RS61734B2 (sr) 2022-04-29
US12133883B2 (en) 2024-11-05
NL301172I2 (nl) 2022-06-16
DK3237014T5 (da) 2024-10-14
EP4218823A3 (en) 2023-11-15
US20170354716A1 (en) 2017-12-14
SI3653227T1 (sl) 2021-04-30
CY1123963T1 (el) 2022-05-27
AU2020270494B2 (en) 2024-02-01
DK3237014T3 (da) 2023-05-30
DK3653227T5 (da) 2023-08-21
SG10202105511RA (en) 2021-07-29
ES2864415T7 (es) 2022-05-12
JP2021020932A (ja) 2021-02-18
ES2947818T3 (es) 2023-08-21
MX394222B (es) 2025-03-24
CY2022013I1 (el) 2023-01-05
CA2968282A1 (en) 2016-05-26
RU2718664C2 (ru) 2020-04-13
MX2022009155A (es) 2022-08-16
EP3653227B9 (en) 2023-03-08
IL251906A0 (en) 2017-06-29
JP2017535609A (ja) 2017-11-30
ES2864415T3 (es) 2021-10-13
FR22C1029I2 (fr) 2023-04-14
IL251906B1 (en) 2023-12-01
NO2022014I1 (no) 2022-05-12
JP2024054177A (ja) 2024-04-16
LT3653227T (lt) 2021-03-25
BR112017009798A8 (pt) 2020-11-03
JP2022033787A (ja) 2022-03-02
DK3653227T3 (da) 2021-02-15
EP3237014A1 (en) 2017-11-01
JP7210683B2 (ja) 2023-01-23
BR112017009798A2 (pt) 2017-12-19
FR22C1029I1 (fr) 2022-09-09
AU2015348633C1 (en) 2021-02-11
HUE053855T2 (hu) 2021-07-28
KR20170084267A (ko) 2017-07-19
KR20230152187A (ko) 2023-11-02
EP3653227B1 (en) 2021-01-20
RU2017121203A3 (el) 2019-05-30
MX2017006113A (es) 2017-10-16

Similar Documents

Publication Publication Date Title
CY2022013I1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK4242916T3 (da) Forstøver
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
EP3230438C0 (en) N-GLYCOSYLATION
FI20155008A7 (fi) Ajoneuvoavusteinen työlaite
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK3183340T3 (da) Termolabile exonukleaser
DE112015001664A5 (de) Betätigungsaktuator
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3094579T3 (da) Bånd-på-bånd transportør
DK3294287T3 (da) Oxabicycloheptan-prodrugs
DE112015005041A5 (de) Gargerätevorrichtung
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
EP3251522C0 (en) FUNCTIONAL FOOD
DK3009858T3 (da) Skyradar
EP3171776C0 (de) Abbildungsanordnung
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
DE202014005655U8 (de) llluminationsvorrichtung
DE112015005055A5 (de) Gargerätevorrichtung